Alkem Laboratories launched NeuCeno (cenobamate) on September 16, 2026, for treating partial-onset seizures in adult patients. This marks the first launch of cenobamate in India.

Product overview

NeuCeno is an anti-seizure medication (ASM) indicated for adults with partial-onset seizures. It is designed as a once daily oral therapy to support patient adherence.

The drug acts through a unique dual mechanism of action:

• Selectively inhibits the persistent sodium current that drives repetitive neuronal firing
• Enhances the brain's natural inhibitory signaling via positive modulation of GABA-A receptors

In randomized clinical studies involving adults with uncontrolled focal seizures on existing medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency. Up to 30% of patients achieved seizure freedom during the maintenance phase.

Launch details

NeuCeno is available in six tablet strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

Epilepsy affects an estimated 9.4 million people in India. Despite multiple available anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, impacting their independence and quality of life.

Management comment

Sandeep Singh, Managing Director, Alkem Laboratories Limited, stated that cenobamate has the potential to transform treatment outcomes for epilepsy management. He noted that patients deserve access to advanced treatment options addressing unmet medical needs.

The launch expands Alkem's neurology portfolio, adding to its existing dominance in anti-infectives, gastrointestinal, pain management drugs, and supplements.

Alkem Laboratories launched Renocia Exo on September 8, 2026. The product is India’s first patented Ginsenoside Exosome-based hair growth serum designed to support follicular health.

The launch addresses rising dermatological concerns regarding hair loss among both ageing adults and younger individuals. The company positioned the therapy as a response to genetic, lifestyle, and environmental stressors driving progressive thinning.

Product Formulation

Renocia Exo integrates multiple regenerative technologies into a single daily therapy. The formulation combines Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives.

Unlike conventional topicals that focus solely on visible growth, the serum targets interconnected biological processes. It aims to support follicular vitality, scalp health, and the natural hair growth cycle by addressing oxidative stress, inflammation, and cellular signalling changes.

Market Context

Sandep Singh, Managing Director of Alkem, noted that the science of hair restoration has evolved significantly over the last decade. He highlighted that hair loss is driven by a complex interplay of mechanisms including follicular miniaturization and altered microenvironments.

The product is free from alcohol, sulphates, silicones, parabens, and mineral oil. It is intended for regular use as part of dermatologist-guided management.

Portfolio Expansion

With this launch, Alkem strengthens its dermatology portfolio. The company leverages its 53-year legacy and presence in chronic therapies to translate emerging scientific insights into therapeutic innovations.

Alkem operates 20 manufacturing facilities and R&D centres across India and the US. It maintains a dominant position in anti-infectives, gastrointestinal, and pain management drugs while expanding in dermatology and urology.